{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:37:02Z","timestamp":1786379822890,"version":"build-2736575974"},"reference-count":57,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K43 TW011387-01A1"],"award-info":[{"award-number":["K43 TW011387-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009648","name":"National Health Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Principal\u2019s New Initiative, Jamaica"},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA006927"],"award-info":[{"award-number":["5P30CA006927"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA221705"],"award-info":[{"award-number":["U54 CA221705"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["R13 CA284826"],"award-info":[{"award-number":["R13 CA284826"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["5U54MD013376"],"award-info":[{"award-number":["5U54MD013376"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In the era of targeted therapeutics, the inadequate representation of Black populations in prostate cancer models limits effective drug screening. In this study, we introduce ACRJ-PC28, a novel Afro-Caribbean prostate cancer cell line, and evaluate its responses to five anticancer drugs (docetaxel, cabazitaxel, abiraterone, olaparib, and enzalutamide) and betaine. We compare these responses with those of established prostate cancer cell lines from Black (MDA-PCA-2b) and White (DU-145 and PC-3) donors using three distinct viability assays. We observed ancestry-dependent drug sensitivities: abiraterone showed remarkable selectivity for ACRJ-PC28 (IC50 = 1.10 \u03bcmol\/L), being 4.6- to 13.1-fold more potent than in other cell lines, whereas enzalutamide demonstrated pronounced racial differences, being 3 to 5 times less effective in cell lines from Black donors (IC50 = 206 \u03bcmol\/L for ACRJ-PC28; 104 \u03bcmol\/L for MDA-PCA-2b) versus cell lines from White donors (IC50 = 37 \u03bcmol\/L for PC-3; 48 \u03bcmol\/L for DU-145). RNA sequencing analysis revealed consistent underexpression of TNF family genes, particularly TNFRSF14, in prostate cancer cells from Black donors correlating with differential drug responses. Despite underexpressing AR, the ACRJ-PC28 line exhibited exceptional sensitivity to abiraterone, consistent with clinical observations that Black patients with prostate cancer respond better to this therapy. This aligns with its neuroendocrine phenotype in the source patient, who succumbed within 1 year despite androgen deprivation therapy. Our findings suggest that incorporating diverse prostate cancer models in preclinical screening could guide personalized treatment strategies for Black patients who experience disproportionate prostate cancer mortality by identifying ancestry-specific drug vulnerabilities that inform optimal therapeutic combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study introduces ACRJ-PC28, the first Afro-Caribbean prostate cancer cell line, revealing ancestry-dependent drug sensitivities that could explain differential clinical outcomes. The findings demonstrate critical gaps in current preclinical models and support incorporating diverse cell lines to develop personalized treatment strategies for underrepresented populations experiencing disproportionate cancer mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0254","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:49:56Z","timestamp":1757958596000},"page":"1758-1770","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5214-3896","authenticated-orcid":false,"given":"Simone","family":"Badal","sequence":"first","affiliation":[{"name":"1Department of Basic Medical Sciences, Faculty of Medical Sciences Teaching and Research Complex, The University of the West Indies, Mona, Jamaica."},{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4455-9266","authenticated-orcid":false,"given":"Bor-Jang","family":"Hwang","sequence":"additional","affiliation":[{"name":"3Center for Health Disparities Research and Innovation, Department of Biology, Morgan State University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4052-5474","authenticated-orcid":false,"given":"Ashlianne","family":"Nelson","sequence":"additional","affiliation":[{"name":"1Department of Basic Medical Sciences, Faculty of Medical Sciences Teaching and Research Complex, The University of the West Indies, Mona, Jamaica."},{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8499-2613","authenticated-orcid":false,"given":"Kristoff","family":"Frank","sequence":"additional","affiliation":[{"name":"1Department of Basic Medical Sciences, Faculty of Medical Sciences Teaching and Research Complex, The University of the West Indies, Mona, Jamaica."},{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2606-2969","authenticated-orcid":false,"given":"Tanisha","family":"Maitre","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"4Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6180-1031","authenticated-orcid":false,"given":"Magdalene","family":"Nwokocha","sequence":"additional","affiliation":[{"name":"5Department of Pathology, University Hospital of the West Indies, Mona, Jamaica."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-4915","authenticated-orcid":false,"given":"Rory","family":"Thompson","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"5Department of Pathology, University Hospital of the West Indies, Mona, Jamaica."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-447X","authenticated-orcid":false,"given":"Belinda","family":"Morison","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"6Section of Surgery, Department of Surgery, Radiology, Anaesthesia and Intensive Care, Faculty of Medical Sciences, The University of the West Indies, Mona, Jamaica."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-8874","authenticated-orcid":false,"given":"Rajini","family":"Haraksingh","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"7Department of Life Sciences, Faculty of Science and Technology, The University of the West Indies, St. Augustine, Trinidad and Tobago."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-4652","authenticated-orcid":false,"given":"Valerie","family":"Odero-Marah","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"3Center for Health Disparities Research and Innovation, Department of Biology, Morgan State University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-4942","authenticated-orcid":false,"given":"Camille","family":"Ragin","sequence":"additional","affiliation":[{"name":"2African Caribbean Cancer Consortium, Philadelphia, Pennsylvania."},{"name":"4Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2025100221250619200_bib1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100221250619200_bib2","first-page":"124","article-title":"A history of cancer and its treatment: Presidential Address to the Ulster Medical Society. 7th October 2021","volume":"91","author":"McAleer","year":"2022","journal-title":"Ulster Med J"},{"key":"2025100221250619200_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/pgs.14.170","article-title":"In vitro human cell line models to predict clinical response to anticancer drugs","volume":"16","author":"Niu","year":"2015","journal-title":"Pharmacogenomics"},{"key":"2025100221250619200_bib4","first-page":"114","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am J Transl Res"},{"key":"2025100221250619200_bib5","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/cncr.33588","article-title":"Prostate cancer survivorship, deaths, and health care management","volume":"127","author":"Bauer","year":"2021","journal-title":"Cancer"},{"key":"2025100221250619200_bib6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025100221250619200_bib7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1055-9965.EPI-21-1064","article-title":"Racial disparities in prostate cancer: evaluation of diet, lifestyle, family history, and screening patterns","volume":"31","author":"Hansen","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025100221250619200_bib8","doi-asserted-by":"crossref","first-page":"10732748221082372","DOI":"10.1177\/10732748221082372","article-title":"Prostate cancer in the Caribbean: a baseline assessment of current practices and potential needs","volume":"29","author":"Khandwala","year":"2022","journal-title":"Cancer Control"},{"key":"2025100221250619200_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41585-019-0234-y","article-title":"The need for cell lines from diverse ethnic backgrounds for prostate cancer research","volume":"16","author":"Badal","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2025100221250619200_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pros.23923","article-title":"Disparities in prostate cancer incidence and mortality rates: solvable or not?","volume":"80","author":"Badal","year":"2020","journal-title":"Prostate"},{"key":"2025100221250619200_bib11","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.3390\/cancers15184558","article-title":"Indirect treatment comparison of first-line CDK4\/6-inhibitors in post-menopausal patients with HR+\/HER2\u2212 metastatic breast cancer","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100221250619200_bib12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"2025100221250619200_bib13","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"2025100221250619200_bib14","first-page":"40","article-title":"Abiraterone for the treatment of advanced prostate cancer","volume":"1","author":"Forde","year":"2012","journal-title":"Int J Target Ther Cancer"},{"key":"2025100221250619200_bib15","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1158\/1078-0432.CCR-15-2638","article-title":"Phase Ib study of enzalutamide in combination with docetaxel in men with metastatic castration-resistant prostate cancer","volume":"22","author":"Morris","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025100221250619200_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14712598.2024.2311750","article-title":"Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations","volume":"24","author":"Tsai","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"2025100221250619200_bib17","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100221250619200_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2767-9764.CRC-22-0245","article-title":"Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient","volume":"2","author":"Valentine","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025100221250619200_bib19","doi-asserted-by":"crossref","first-page":"e0272396","DOI":"10.1371\/journal.pone.0272396","article-title":"Targeted non AR mediated smart delivery of abiraterone to the prostate cancer","volume":"17","author":"Baker","year":"2022","journal-title":"PLoS One"},{"key":"2025100221250619200_bib20","first-page":"513","article-title":"Betaine induces apoptosis of C4-2B prostate cancer cells via inhibiting PI3K\/AKT\/NF-\u03baB signaling pathway","volume":"37","author":"Zhang","year":"2021","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"2025100221250619200_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/pharmaceutics15020662","article-title":"Cabazitaxel-loaded nanoparticles reduce the invasiveness in metastatic prostate cancer cells: beyond the classical taxane function","volume":"15","author":"Lampe","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025100221250619200_bib22","first-page":"3864","article-title":"Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells","volume":"19","author":"Yang","year":"2019","journal-title":"Mol Med Rep"},{"key":"2025100221250619200_bib23","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.3390\/cancers14163877","article-title":"Development of olaparib-resistance prostate cancer cell lines to identify mechanisms associated with acquired resistance","volume":"14","author":"Cahuzac","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100221250619200_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s42003-022-03210-5","article-title":"Pre-activation of autophagy impacts response to olaparib in prostate cancer cells","volume":"5","author":"Cahuzac","year":"2022","journal-title":"Commun Biol"},{"key":"2025100221250619200_bib25","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/15353702211012625","article-title":"Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes","volume":"246","author":"Feng","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"2025100221250619200_bib26","article-title":"CellTiter 96\u00ae non-radioactive cell proliferation assay Technical Bulletin #112. Madison (WI): Promega Corporation; 1991\u20132012","author":"Promega Corporation"},{"key":"2025100221250619200_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-6960-9_1","article-title":"Basic colorimetric proliferation assays: MTT, WST, and resazurin","volume":"1601","author":"Pr\u00e4bst","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2025100221250619200_bib28","doi-asserted-by":"crossref","first-page":"giz106","DOI":"10.1093\/gigascience\/giz106","article-title":"Evaluating stably expressed genes in single cells","volume":"8","author":"Lin","year":"2019","journal-title":"Gigascience"},{"key":"2025100221250619200_bib29","article-title":"The European Nucleotide Archive (ENA) is part of the ELIXIR infrastructure","author":"European Nucleotide Archive","year":"2023"},{"key":"2025100221250619200_bib30","article-title":"A quality control tool for high throughput sequence data","author":"Andrews","year":"2024"},{"key":"2025100221250619200_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"2025100221250619200_bib32","article-title":"Search human (Homo sapiens)","author":"Ensembl","year":"2024"},{"key":"2025100221250619200_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025100221250619200_bib34","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/gb-2010-11-2-r14","article-title":"Gene ontology analysis for RNA-seq: accounting for selection bias","volume":"11","author":"Young","year":"2010","journal-title":"Genome Biol"},{"key":"2025100221250619200_bib35","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/bioinformatics\/btt285","article-title":"Pathview: an R\/Bioconductor package for pathway-based data integration and visualization","volume":"29","author":"Luo","year":"2013","journal-title":"Bioinformatics"},{"key":"2025100221250619200_bib36","doi-asserted-by":"crossref","first-page":"W3","DOI":"10.1093\/nar\/gkw343","article-title":"The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update","volume":"44","author":"Afgan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025100221250619200_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2191-2858-2-21","article-title":"Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata","volume":"2","author":"Badal","year":"2012","journal-title":"Org Med Chem Lett"},{"key":"2025100221250619200_bib38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-018-4848-x","article-title":"Genomic analysis of DNA repair genes and androgen signaling in prostate cancer","volume":"18","author":"Jividen","year":"2018","journal-title":"BMC Cancer"},{"key":"2025100221250619200_bib39","first-page":"1934578X231175323","article-title":"Augmentation of docetaxel-induced cytotoxicity in human PC-3 androgen-independent prostate cancer cells by combination with four natural apoptosis-inducing anticancer compounds","volume":"18","author":"Ahmed","year":"2023","journal-title":"Nat Prod Commun"},{"key":"2025100221250619200_bib40","first-page":"440","article-title":"Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer","volume":"37","author":"Nightingale","year":"2012","journal-title":"P T"},{"key":"2025100221250619200_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2021.10.016","article-title":"Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial","volume":"81","author":"Baciarello","year":"2022","journal-title":"Eur Urol"},{"key":"2025100221250619200_bib42","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/cncr.33589","article-title":"A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer","volume":"127","author":"George","year":"2021","journal-title":"Cancer"},{"key":"2025100221250619200_bib43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","article-title":"Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy","volume":"74","author":"Lawrence","year":"2018","journal-title":"Eur Urol"},{"key":"2025100221250619200_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bbrc.2006.09.049","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"2025100221250619200_bib45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.29252\/ibj.23.5.2","article-title":"Novel poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells","volume":"23","author":"Sargazi","year":"2019","journal-title":"Iran Biomed J"},{"key":"2025100221250619200_bib46","first-page":"305","article-title":"Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia","volume":"29","author":"Soulitzis","year":"2006","journal-title":"Int J Oncol"},{"key":"2025100221250619200_bib47","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2025100221250619200_bib48","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.7150\/thno.40559","article-title":"Megakaryocytes promote bone formation through coupling osteogenesis with angiogenesis by secreting TGF-\u03b21","volume":"10","author":"Tang","year":"2020","journal-title":"Theranostics"},{"key":"2025100221250619200_bib49","doi-asserted-by":"crossref","first-page":"e51019","DOI":"10.7554\/eLife.51019","article-title":"Replication Study: a coding-independent function of gene and pseudogene mRNAs regulates tumour biology","volume":"9","author":"Kerwin","year":"2020","journal-title":"Elife"},{"key":"2025100221250619200_bib50","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0022-5347(05)68158-X","article-title":"Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a","volume":"162","author":"Zhao","year":"1999","journal-title":"J Urol"},{"key":"2025100221250619200_bib51","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100221250619200_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s12192-019-01022-x","article-title":"Betaine suppresses cell proliferation by increasing oxidative stress-mediated apoptosis and inflammation in DU-145 human prostate cancer cell line","volume":"24","author":"Kar","year":"2019","journal-title":"Cell Stress Chaperones"},{"key":"2025100221250619200_bib53","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3892\/ijo.2012.1616","article-title":"Betaine inhibits in vitro and in vivo angiogenesis through suppression of the NF-\u03baB and Akt signaling pathways","volume":"41","author":"Yi","year":"2012","journal-title":"Int J Oncol"},{"key":"2025100221250619200_bib54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12967-017-1233-5","article-title":"Betaine promotes cell differentiation of human osteoblasts in primary culture","volume":"15","author":"Villa","year":"2017","journal-title":"J Transl Med"},{"key":"2025100221250619200_bib55","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025100221250619200_bib56","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2025100221250619200_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12672-014-0190-1","article-title":"Androgen receptor splice variants in the era of enzalutamide and abiraterone","volume":"5","author":"Nakazawa","year":"2014","journal-title":"Horm Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0254\/3651030\/crc-25-0254.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/10\/1758\/3657056\/crc-25-0254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/10\/1758\/3657056\/crc-25-0254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:25:24Z","timestamp":1759454724000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/10\/1758\/766028\/Novel-Afro-Caribbean-Prostate-Cancer-Model-Reveals"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0254","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8068663","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30268429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30268435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30268426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30268432","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}